DPP4 and diabetes mellitus: Incretin mimetics known as glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, both used in diabetes treatment, have been associated with the upregulation of SIRT1.